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and Andreas Stang1,5Abstract
Background: To examine the all-cause mortality and uveal melanoma specific mortality among newly diagnosed
uveal melanoma patients after five years. Furthermore, we assess of the effect of iris colour and having children on
5-year risk of death after diagnosis of uveal melanoma. Therefore, we assess the performance of an individual
prediction model of survival from uveal melanoma.
Methods: A cohort of 459 patients aged 45 to 79 years with newly diagnosed uveal melanoma was recruited
between 2002 and 2004 from the Division of Ophthalmology, University of Essen, Germany. Survival probabilities
were estimated by Kaplan-Meier survival analysis. The clinical and histopathological characteristics were obtained
from medical records. Iris colour and childbearing history were assessed at baseline by a computer-assisted
telephone interview. We used crude and multivariable Cox proportional hazards regression to estimate unadjusted
and adjusted hazard ratios (HR) and corresponding 95% confidence intervals (95%CIs) with respect to death from
uveal melanoma and death from all causes. We used the Cox model to estimate adjusted probabilities of primary
events. For computing Harrell’s C statistics, we used a Cox model including the prognostics factors gender, age at
diagnosis, ciliary body involvement, largest basal tumour diameter, and iris colour.
Results: The 5-year uveal melanoma-specific survival probability was 82.9% (95% CI: 79.1-86.3). Main prognostic
factors for the death of uveal melanoma were ciliary body involvement (HR: 1.7 (95% CI:1.0-2.8)), largest basal
tumour diameter >15 mm HR: 7.0 (95% CI: 3.5-13.9), light iris colour (HR: 2.3 (95% CI: 0.9-5.8), having children
(HR: 0.6 (95% CI: 0.2 - 1.7)), and gender (HR: 0.7 (95% CI: 0.4-1.1)). The value of the bootstrap-corrected C statistics
was 0.76 (95% CI: 0.74-0.77).
Conclusion: Beyond the established prognostic factors, light iris colour also appears to be a prognostic factor for
death from uveal melanoma.
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Although a rare disease, uveal melanoma of the eye is
the most common primary intraocular malignancy in
adults, with an incidence rate of up to 8 per 1,000,000
person years (age-standardised, world standard) in Europe
[1,2] and the fatality rate is high despite modern treatment
modalities. Bergman et al. reported an observed survival* Correspondence: andrea.schmidt-pokrzywniak@uk-halle.de
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article, unless otherwise stated.after 5 and 10 years of 60% and 43%, respectively. The
relative survival, taken as the estimate of the probability
of death due to uveal melanoma was 70% after 5 years
(68% in men and 72% in women) and 59% after 10 years
(58% in men and 61% in women), respectively [3]. In the
European Cancer Registry (EUROCARE)–based study
of survival and care of patients with cancer, which in-
cluded data from 67 cancer registries with a combined
population of 100 million persons in 22 European coun-
tries, the 5-year relative uveal melanoma survival ranged
from 63% to 71% [4]. Patients are at risk of developingioMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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http://www.biomedcentral.com/1471-2415/14/42metastases up to 20 years after the initial diagnosis. The
most common site for metastatic uveal melanoma is the
liver. 80% of metastatic patients die within one year and
92% within 2 years of the diagnosis of metastases [5].
Uveal melanomas affect both sexes at equal rates, but
the reported disease-specific mortality is higher among
men [4,6]. The risk of death was 10% higher in males
than in female patients and was about 2 and 2.5 times
higher, respectively, in the groups aged 55 to 64 years
and 75 years or older compared with the group aged
54 years or younger [4]. An important predictor of time
to death is the largest basal tumour diameter. In the
Collaborative Ocular Melanoma Study (COMS), Hawkins
et al. found cumulative age adjusted rates of death from
any cause at 5 years after diagnosis of 49% with a ma-
ximum basal tumour diameter of ≥18 mm and of 31%
with a diameter of <18 mm, respectively [7]. Further prog-
nostic factors include the involvement of the ciliary body,
extrascleral extension, and an inflammatory phenotype
[8]. Specific genetic alterations that are associated with the
development of metastases have been identified, such as
monosomy [8,9]. Several studies have shown that mono-
somy 3 is also an important prognostic factor with regard
to predicting death due to metastatic disease [8-10].
Damato et al. reported that the best predictive index can
be obtained by using several parameters, including mono-
somy 3, basal tumour diameter, and epithelioid cellularity,
creating a combined prognostic index [10]. Several studies
showed that light iris colour is one of the established risk
factors for uveal melanoma, [11-13] but only one study
has examined the association between light iris colour and
the risk of death from uveal melanoma [14]. Regan et al.
found that patients with blue or grey irises had a 2-fold in-
creased risk of metastatic death from uveal melanoma, in-
dependent of other risk factors, compared to those with
darker irises [14]. Another study showed that overall ad-
justed death rates from metastasis were approximately
25% higher in nulliparous women than in women who
had given birth. The protective influence of parity was
strongest in the early period following diagnosis and treat-
ment. The level of protection increased with the number
of live births [15].
Today, the majority of patients are treated by eye-
preserving therapies (63%) [5,16], which mainly involve
radiation brachytherapy and teletherapy. Estimates of
prognosis among these patients can be based only on
clinical factors. Cook et al. found that the majority of pa-
tients want to know their prognosis for survival, even
when they are told that prognostication is unlikely to im-
prove their chances of prolonging life [17]. The patients
who are most distressed are those who cannot be given a
prognosis because genetic testing has failed [18].Therefore
it is necessary to identify further prognostic factors which
are relevant for death from uveal melanoma that are notbased on histological and/or genetics factors. The purpose
of our study was to investigate the all-cause mortality and
uveal melanoma specific mortality among newly diag-
nosed uveal melanoma patients after five years. Further-
more, we assessed the association between iris colour and
having children on the risk of death from uveal melanoma.
In addition, we assess the individual prediction perfor-




The analysis was based on a cohort of 459 patients aged 25
to 79 years with a diagnosis of uveal melanoma between
2002 and 2004. The baseline case recruitment was hospital-
based and took place in the Division of Ophthalmology,
University of Essen, which is a referral centre for eye cancer
in Germany. Cases were defined as patients with uveal
melanoma as identified by the International Classification
of Diseases, Tenth Revision (ICD-10) as C69.3 (Choroid) or
C69.4 (Ciliary body) and by International Classification of
Diseases for Oncology morphology codes 8720/3 to 8774/3
(uveal melanoma) [19]. To evaluate vital status during
follow-up we sent a questionnaire to all 459 patients
after a median follow-up time of 58.4 months. After
repeated mailings to non-respondents, we received an-
swers from 77% of the patients. For the remaining non-
respondents we evaluated the vital status via registration
residents’ offices.
The study was approved by the ethics committee of
the Medical Faculty in Essen, Germany (01-113-1713).
Informed consent was obtained from all responding
patients.
Exposure assessment and outcome
The clinical and histopathological characteristics were ob-
tained from medical records. Iris colour and childbearing
history were assessed at baseline by a computer-assisted
telephone interview (CATI) [19]. The CATI contained a
question about eye colour with the following categorical
answers: blue, grey, green, hazel, brown, and black. Fur-
thermore, women were asked: how many children do you
have (including already deceased children)? The informa-
tion on cause of death was based on official death certifi-
cates in 89%, statements from patients’ ophthalmologists
and/or general physicians in 2%, and on statements from
relatives or friends in 9%. The statements were retrieved
by personal interviews.
Statistical analysis
Survival probabilities were estimated by Kaplan-Meier
survival analysis. We used crude and multivariable Cox
proportional hazards regression to estimate unadjusted
and adjusted hazard ratios (HR) and corresponding 95%
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http://www.biomedcentral.com/1471-2415/14/42confidence intervals (95%CIs) with respect to death
from uveal melanoma and death from all causes. We
checked the assumption of proportional hazards by use
of Schoenfeld residual plots. We used the Cox model to
estimate adjusted probabilities of primary events based
on mean values of the covariates in the model. We identi-
fied minimally sufficient adjustment sets depending on the
outcome using causal diagrams that represented the pre-
sumed associations between exposure, outcome, and other
variables [20]. For computing Harrell’s C statistics, we















Largest basal tumour diameter (mm)
≤ 10 168 37.6
> 10 - ≤15 197 42.9

















1)grey, blue, green, hazel 2)brown, black.gender, age at diagnosis, ciliary body involvement, lar-
gest basal tumour diameter, and iris colour as covariates
and corrected for over-optimism by bootstrapping (1000
runs) [21]. The over-optimism-corrected C statistics is
given with a non-parametric 95% bootstrap confidence
interval. A value of 0.5 indicates that the model is no bet-
ter than chance at predicting the outcome, while a value
of 1.0 indicates that the model perfectly identifies the out-
come. Models are typically considered reasonable when
the C-statistic is higher than 0.7 and strong when C ex-
ceeds 0.8 [21]. All analyses were performed using thepatients; treated in Germany, Essen 2002-2004
Women Men
N % N %
216 47 243 53
46 21.2 44 18.1
56 26.0 55 25.5
83 38.4 109 44.8
31 14.4 35 14.4
39 18.0 45 18.5
82 37.9 73 30.0
87 40.3 111 45.8
2 0.9 5 2.0
6 2.9 9 3.7
78 36.1 90 37.0
104 48.1 93 38.3
28 13.0 51 21.0
6 2.8 9 3.7
2 0.9 5 2.1
2 0.9 5 2.1
172 80.0 196 81.7
43 20.0 44 18.3
1 0.5 3
190 88.0 207 85.2
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conducted in accordance with the German guidelines of
Good Epidemiological Practice [23].
Results
Patient baseline characteristics are given in Table 1.
In 79% of the 459 cases only the choroid was involved,
in 1% only the ciliary body, in 2% the iris, and in 18% the
ciliary body and other parts of the uvea were involved.
With regard to primary therapy, 12% of the cases under-
went enucleation, 67% were treated by brachytherapy, 9%
by proton beam radiotherapy, 6% by stereotactic radiother-
apy, 2% by transpupillary thermotherapy, and 4% by other
eye-preserving therapies. Among women, 51% of tumours
were diagnosed in the left eye, while this was 56% in men.
Follow-up data
The median follow-up time was 58 months. Follow-up
data were available from 457 (99.5%) patients; two patients
were lost to follow-up. During the follow-up period, 95
patients (22%) died, of whom 79 (83%) died due to meta-
static melanoma and 11 died from other causes (12%). In
5 patients (5%), the cause of death is unknown.
Survival analysis
Kaplan–Meier analysis revealed a 5-year overall sur-
vival probability of 79.8% (95% CI: 75.9-83.5), and uveal
melanoma-specific survival of 82.9% (95% CI: 79.1-86.3),
(Figure 1).
Table 2 presents estimated hazard ratios (HR) of over-
all mortality and uveal melanoma-specific mortality ac-
cording to different prognostic factors. We found a 30%Figure 1 Survival probabilities for overall and disease-specific survivadecreased HR of death from all causes and from uveal
melanoma-specific deaths for women compared to men.
After adjustment for ciliary body involvement and basal
tumour diameter, the 5-year probability of uveal melan-
oma death was 10.9% (95% CI: 6.5-15.1) for women and
16.2% (95% CI: 10.9-21.2) for men (Figure 2a). Increasing
basal tumour diameter was associated with an increased
HR of uveal melanoma death (Figure 2b). By ciliary body
involvement, the adjusted 5-year probability of uveal mel-
anoma death was nearly doubled compared with no ciliary
body involvement (21.0% (95% CI: 11.4-29.5) versus 12.2%
(95% CI: 8.5-15.7)) (Figure 2c). Patients with light iris
colour had an adjusted 2.3-fold increased risk of overall
and uveal melanoma-specific death compared to brown or
black iris colour (Table 2). The adjusted 5-year probabil-
ity of uveal melanoma death for patients with light iris
colour was 14.6% (95% CI: 10.5-18.6), and for patients
with dark iris colour 7.2% (95% CI: 0.7-13.2), respec-
tively (Figure 2d). The adjusted HR for women with
children was 0.6 (95% CI: 0.2 - 1.7) compared to women
without children. An increasing number of children did
not lead to a decrease in HR estimates.
The value of the bootstrap-corrected C statistics was
0.76 (95% CI: 0.74-0.77), indicating a satisfactory predic-
tion performance of the model.Discussion
In our study, we observed a 5-year overall survival of
79.8% and a uveal melanoma-specific survival of 82.9%.
Men had a higher overall- and uveal melanoma-specific
mortality than women [6]. Damato et al. found that uveal
melanomas tend to be larger and more posterior in menl among 459 uveal melanoma patients, Germany, 2002–2010.
Table 2 Estimated hazard ratios of overall mortality and melanoma-specific mortality by patient characteristics
Patients Number of death Overall mortality N = 95 Melanoma-specific mortality N = 79
N % N HR1) (95% CI)2) HR3) (95% CI) HR1) (95% CI) HR3) (95% CI)
Gender
Men 216 47.1 60 1.0 1.0 7) 1.0 1.0 7)
Women 243 52.9 35 0.6 (0.4 - 0.9) 0.7 (0.4 - 1.0) 0.6 (0.4-1.0) 0.7 (0.4 - 1.1)
Largest basal tumour diameter (mm)
≤ 10 168 36.6 21 1.0 1.0 8) 1.0 1.0 8)
> 10 - ≤15 197 42.9 34 1.4 (0.8 - 2.5) 1.3 (0.8 - 2.3) 2.2 (1.1 - 4.3) 2.0 (1.0 - 4.0)
> 15 79 17.2 38 5.1 (3.0 - 8.8) 4.2 (2.4 - 7.4) 8.4 (4.2 – 16.1) 7.0 (3.5 - 13.9 )
Extra ocular growth
No 451 98.3 1.0 1.0 8) 1.0 1.0 8)
Yes 7 1.5 2 1.7 (0.4 - 7.0) 1.2 (0.3 - 4.8) 2.0 (0.5 - 8.2) 1.2 (0.3 - 4.8)
Ciliary body involvement
No 368 80.2 60 1.0 1.0 9) 1.0 1.0 9)
Yes 87 19.0 34 2.7 (1.8 - 4.2) 1.8 ( 1.1 - 2.8) 3.0 (1.9 - 4.7) 1.7 (1.0 - 2.8)
Iris colour
Dark4) 62 13.5 7 1.0 1.0 7) 1.0 1.0 7)
Light5) 397 86.5 88 2.1 (1.0 - 4.5) 2.0 (0.9 - 4.3) 2.4 (1.0-6.0) 2.3 (0.9 - 5.8)
Children6)
No 28 13.0 7 1.0 1.0 10) 1.0 1.0 10)
Yes 188 87.0 28 0.5 (0.2 - 1.2) 0.4 (0.2 - 1.0) 0.7 (0.3 - 1.7) 0.6 (0.2 - 1.7)
Number of children
0 28 12.9 7 1.0 1.0 8) 1.0 1.0 8)
1 62 28.7 10 0.6 (0.2 - 1.6) 0.5 (0.2 - 1.4) 0.8 (0.3 - 2.3) 0.7 (0.2 - 2.3)
2 87 40.3 12 0.5 (0.2 - 1.3) 0.4 (0.2 - 1.1) 0.5 (0.2 - 1.6) 0.5 (0.2 - 1.5)
≥3 39 18.1 6 0.6 (0.2 - 1.6) 0.4 (0.1 - 1.3) 0.8 (0.2 - 2.5) 0.7 (0.2 - 2.5)
1)crude Hazard Ratio 2)95% Confidence Interval 3)adjusted Hazard Ratio.
4)brown, black iris colour 5)grey, blue, green, hazel iris colour.
6)only women.
7)adjusted for ciliary body involvement and largest basal tumour diameter 8)adjusted for ciliary body involvement 9)adjusted for largest basal tumour diameter
10)adjusted for age and graduation.
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ity in men could be that women usually contact their
physician earlier when a problem occurs. Thus a treat-
ment can be initiated before the situation has evolved too
dramatically, resulting in better treatment outcome [24].
Our survival rates are comparable with other studies
[5,15,25-27]. However, the reported survival rates are diffi-
cult to compare because of differences in the correspond-
ing populations of uveal melanoma patients (differences
in age, tumour characteristics, and tumour staging). As
our and other studies have shown, large tumour diameters
and ciliary body involvement are established prognostic fac-
tors for uveal melanoma-specific mortality [3,5,16,28,29].
Patients in our study with the largest tumour diameter of
greater than 15 millimetres had a nearly 7-fold increased
risk of uveal melanoma death compared to patients with
a largest tumour diameter smaller than 10 millimetres.
We also identified ciliary body involvement to be anindependent clinical prognostic factor. The increased
5-year mortality of 21% in patients with ciliary body in-
volvement observed in our study is in line with that
reported in other studies [6,16,28]. In large uveal melano-
mas, the ciliary body is more likely to be involved [30].
Furthermore, they are more likely to show adverse histo-
logical and genetic risk factors [10]. Rummel et al.
concluded that the poor prognosis for ciliary body in-
volvement might partly be explained by the tendency for
these tumours to have microvascular networks and loops,
which are associated with uveal melanoma death [31].
We found an association between iris colour and uveal
melanoma death. Patients with light iris colour had a
2.3-fold increased risk of death from uveal melanoma
compared to patients with dark iris colour, independent
of other prognostic factors. This was in line with the
study by Regan et al., which was the only study that ex-
amined the prognostic influence of iris colour on uveal
Figure 2 Estimated probabilities of uveal melanoma death. (a) stratified by gender adjusted for ciliary body involvement and largest basal
tumour diameter among 459 uveal melanoma patients, Germany, 2002–2010, (b) stratified by largest basal tumour diameter adjusted for ciliary
body involvement among 459 uveal melanoma patients, Germany, 2002–2010, (c) stratified by ciliary body involvement adjusted for largest basal
tumour diameter among 459 uveal melanoma patients, Germany, 2002–2010, (d) stratified by iris colour adjusted for ciliary body involvement
and largest basal tumour diameter among 459 uveal melanoma patients, Germany, 2002–2010.
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the tumours of patients with light iris colour were closer
to the optic disc and macular, which is the region of the
choroid that is most directly exposed to ultraviolet (UV)
radiation [14]. Some case–control studies, including our
own study on risk factors associated with uveal melanoma,
reported a positive association between UV radiation and
uveal melanoma risk [11,13]. Our case–control study
found synergistic effects between light iris colour and
UV radiation. This interaction analysis suggested that
there is an aetiological synergism between light iris
colour and exposure to UV radiation [13]. However,
the role that light iris colour plays in the metastatic
spread of this tumour is unclear. Regan et al. con-
cluded that specific genetic lesions of uveal melano-
cytes resulting from UV radiation promote uveal
melanoma, and this is associated with a more aggres-
sive form of the disease [14].
In addition, our results indicate that women with chil-
dren have a reduced risk of uveal melanoma death. Our
findings are in line with the results from Egan et al.;
however, our estimations were not precise [15]. An ex-
planation for this protective effect could be a potentialmechanism by which women are “naturally immunised”
against cancer antigens by antigens from their foetus.
Evidence from recent clinical studies has shown that a high
percentage of parous women, but not nulliparous women,
showed evidence of immunisation against antigens found
against breast, ovarian and endometrial cancer [32].
The usefulness of the risk factors, if collected in a single
score, for individual risk prediction was moderate. It is
well known that prediction models based on risk factors,
even when strongly associated with disease or outcome,
are not good predictors for an individual patient [33].
The strengths of our study are the nearly complete
follow-up of our patients (99.5%), and survival estimates
based on data collected from multiple sources, including
death certificates, patients’ ophthalmologists and/or
general physicians, as well as from the Division of
Ophthalmology, University of Essen, where the patients
were treated.
Weaknesses include the fact that some benign lesions,
such as choroidal naevi, may have been classified as uveal
melanomas, resulting in an overestimation of survival
from uveal melanoma. Another limitation is related to
the analysis regarding children as a prognostic factor: we
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have biological children” which would have been more
precise. This, in turn, could lead to a slight overestimation
of the number of children. Furthermore, this is a secon-
dary analysis from an original case–control study designed
to examine the associations between radiofrequency radi-
ation and the risk of developing uveal melanoma. [19] For
the current project, only participants identified as cases
were relevant.
Conclusion
We summarized, light iris colour appears to be not only
a risk factor for uveal melanoma but also a prognostic
factor for death due to uveal melanoma. More research
is needed to firmly establish this link.
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